Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

被引：0
|
作者：
Roboz, Gail J. [1 ]
Larson, Melissa L. [2 ]
Rubenstein, S. Eric [3 ]
Solomon, Scott R. [4 ]
Schiller, Gary J. [5 ]
An, Qi [6 ]
Mancino, Emaryn [6 ]
Chiarella, Michael [6 ]
Louie, Arthur C. [6 ]
Lin, Tara L. [7 ]
机构：
[1] Cornell Univ, Div Hematol & Oncol, Weill Cornell Med Coll, New York, NY 10021 USA
[2] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[3] Franciscan Hlth, Indianapolis, IN USA
[4] Northside Hosp Canc Ctr Inst, Leukemia Program, Atlanta, GA USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[6] Jazz Pharmaceut, Palo Alto, CA USA
[7] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1434
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia
    Roboz, Gail J.
    Larson, Melissa L.
    Rubenstein, S. Eric
    Solomon, Scott R.
    Schiller, Gary J.
    An, Qi
    Chiarella, Michael
    Louie, Arthur C.
    Lin, Tara L.
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1188 - 1194
  • [2] Efficacy and Safety Profile of CPX-351 in Secondary Acute Myeloid Leukemia (sAML): A Systematic Review
    Ibrahim, Ahmed
    Yousaf, Muhammad Abdullah
    Ikram, Mariam
    Khalid, Huma
    Anum
    Safdar, Omar A.
    Anwer, Zain
    Faraz, Fatima
    Rehman, Mohammad
    Saad, Muhammad
    [J]. BLOOD, 2023, 142
  • [3] CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia
    Assi, Rita
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias J.
    Gborogen, Rosilyn A.
    Chamoun, Kamal
    Wierda, William G.
    Borthakur, Gautam
    Cortes, Jorge E.
    [J]. BLOOD, 2016, 128 (22)
  • [4] CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia
    Thomas, Xavier
    Plesa, Adriana
    [J]. LANCET HAEMATOLOGY, 2021, 8 (07): : E468 - +
  • [5] Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia
    Przespolewski, Amanda
    Goldberg, Aaron D.
    Talati, Chetasi
    Fazal, Salman
    Vachhani, Pankit
    Sanikommu, Srinivasa R.
    Thota, Swapna
    Waksal, Julian
    Ball, Brian
    Famulare, Christopher
    Stahl, Maximilian
    Baron, Jeffrey
    Griffiths, Elizabeth A.
    Thompson, James E.
    Sweet, Kendra
    Wang, Eunice S.
    [J]. BLOOD, 2023, 141 (12) : 1489 - 1493
  • [6] Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
    Kolitz, Jonathan E.
    Strickland, Stephen A.
    Cortes, Jorge E.
    Hogge, Donna
    Lancet, Jeffrey E.
    Goldberg, Stuart L.
    Villa, Kathleen F.
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur C.
    Ritchie, Ellen K.
    Stuart, Robert K.
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 631 - 640
  • [7] Real-world experience with CPX-351 in high-risk acute myeloid leukemia
    Lemoli, Roberto M.
    Montesinos, Pau
    Jain, Akriti
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 185
  • [8] Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).
    Lin, Tara L.
    Medeiros, Bruno C.
    Uy, Geoffrey L.
    Newell, Laura Fugal
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen Anthony
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur Chin
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] CPX-351 TREATMENT IN SECONDARY ACUTE MYELOID LEUKEMIA (SAML): THE REAL LIFE EXPERIENCE FROM THE "ITALIAN TRIVENETO REGISTRY"
    Fili, C.
    Candoni, A.
    Mauro, E.
    Scattolin, A. M.
    Leoncin, M.
    Gurrieri, C.
    Nadali, G.
    Mosna, F.
    Michieli, M. G.
    Lico, A.
    Lazzarotto, D.
    Zannier, M. E.
    Simeone, E.
    Facchin, G.
    Battaglia, G.
    Gherlinzoni, F.
    Bassan, R.
    Semenzato, G.
    Fanin, R.
    [J]. HAEMATOLOGICA, 2021, 106 (10) : 128 - 129
  • [10] CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
    Talati, Chetasi
    Lancet, Jeffrey E.
    [J]. FUTURE ONCOLOGY, 2018, 14 (12) : 1147 - 1154
12345